With nearly ten million new cases of active disease each year, TB is now the leading cause of death from infectious disease globally. 2 Current therapeutic strategies involve the use of a combination of anti-microbial agents including ethambutol, isoniazid, pyrazinamide and rifampicin ( fig. 1 ). 3 However, more than 5% of Mtb infections now involve multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) Mtb strains. MDR-TB is associated with a 50% mortality rate whereas XDR-TB is nearly always fatal. 4 There is an urgent need for new therapeutic strategies.
Human protein kinases are pharmacologically tractable enzymes targeted by more than three dozen approved medicines. 5 Hundreds of additional kinase inhibitors are under clinical and preclinical investigation. There is growing recognition that pathogen kinases may be targeted in the treatment of infectious diseases. [6] [7] Considering the conserved ATP-binding site across species, we looked to screen collections of ATP-competitive inhibitors of human kinases for their anti-tubercular activity.
There have been several efforts to map the ATP-competitive inhibitor landscape, notably with the first-and second-generation GlaxoSmithKline Published Kinase Inhibitor Sets (PKIS and PKIS2), collections of well characterized ATP-competitive kinase inhibitors with broad coverage of the human kinome. [8] [9] These sets and wider inhibitor screening efforts have found utility in identifying inhibitors of additional human kinases as well as kinases from other organisms, both eukaryotic and prokaryotic. [10] [11] [12] [13] [14] To identify new chemical starting points against Mtb we looked to lapatinib, gefitinib, and erlotinib as starting points which have recently been revealed to have activity against Mtb (Fig. 2.) . 5, 15 We tested the activity of lapatinib, gefitinib, and erlotinib against Mtb by measuring luminescence and growth on solid medium across a series of compound concentrations (20 -0.625 µM) (Tab 2). [16] [17] The reduction of visible growth on solid medium demonstrated the compounds to be bactericidal.
Gefitinib treatment had no effect relative to the absence of compound. Erlotinib induced a modest effect that appeared to plateau at a signal of approximately 70 %. In contrast, lapatinib showed activity even at 5 µM and reduced the relative Mtb signal to below 10 % at 20 µM. This result suggested that the 4-benzyloxy aniline substituent might be important for anti-Mtb activity. To further explore quinazoline Mtb activity, we profiled several focused arrays of compounds to probe the structure activity relationships of the quinoline/quinazoline. We hence synthesized a series of compounds (1-34) following up on GW320571X, a PKIS2 quinazoline, through nucleophilic aromatic displacement of 4-chloroquin(az)olines. (Scheme 1) We were able to access products in good to excellent yields (55-91 %) consistent with previous reports and without protection of the alcohol substituted quin(az)oline starting material. 10, 18 Scheme 1. General synthetic procedure
The first set of compounds probed a replacement of the 6-postion morpholine segment of gefitinib with a simple alcohol (Tab. 2).
20 Although neither the 6-OH (1) or 7-OH (2) quinazoline showed appreciable activity, the 6,7-dihydroxy compound (3) began to inhibit Mtb growth at higher concentrations. The analogous set of methoxy-substituted compounds (4-6) had very similar activity profiles. The 6-OH quinoline (7) showed improved activity relative to the matched quinazoline (1). The inclusion of fluorine substitution on the phenyl ring distal to the quinazoline (8-10) led to markedly increased activity for all three isomers. At 20 µM, 8-10 all reduced the relative Mtb signal to 25-37 %, and a modest but discernable reduction in signal was observed at 1.25 µM. Interestingly, the effect of fluorine substitution led to a different activity pattern from changing quinazoline ring substitution as the modification of 1 to the 7-OH (11) or 6,7-(OH) 2 (12) resulted in a significant loss of activity, even at 20 µM. These results demonstrated that Mtb activity was sensitive to changes at multiple parts of the template and that these changes were not necessarily additive.
The next set of quin(az)olines profiled was prepared to explore the contributions from both the aniline and the core heterocycle (Tab. 3). 18, 21 The larger 3,4,5-trimethoxyphenyl aniline was employed on several diversely substituted quinolines and a Relative luminescence measured at 3 days after treatment. Values = RLU(sample)/RLU(no compound) at µ M concentrations and no effect at 0.625 µ M quinazolines (13) (14) (15) (16) (17) (18) which led to no observable activity except when paired with the 6,7-(OCH 2 CH 2 OMe) 2 -quinazoline of erlotinib (19) which had only slight activity at 20 µM. On the other hand, incorporation of the aniline fragment from erlotinib (3-ethynylphenyl) did yield several active compounds, including the quinoline analog of erlotinib (20). The erlotinib aniline with a 6,7-(OMe) 2 -substituted quinoline core (21) or quinazoline (22) showed activity but not with the 3-cyanoquinoline (23). The analogous 3-bromophenyl aniline compounds (24-26) showed higher activity than the paired 3-ethynylphenyl compounds. Finally, the aniline substitution from lapatinib (3-Cl-4-(2-FPhO)Ph) yielded a marginally active quinazoline (27) and a highly active quinoline (28) that had 10 % Mtb signal at 20 µM.
A final small set of compounds explored features of the 4-benzyloxyaniline portion of the quinoline template (Tab. 4).
22
Variation of the ether linkage to an amide and addition of a hydroxy on the aniline portion revealed an activity pattern where 6,7-dimethoxy substitution with the benzylic arm was active (29-30). In contrast, truncation of the benzyl also removed the activity as in acetamide 31 with no effect on Mtb. The monosubstituted 6-methoxy (32) and 7-methoxy (33) showed no reduction in Mtb signal at 20 µM. However, switching back to the 4-methyl benzyl ether linked compound 34 yielded the highest activity observed with any compound in the present study, with a robust signal observed even at 1.25 µM. The Mtb MIC 99 for 34 was in the 1.25-2.5 µM range (Fig. 3) .
These results define a series of structure activity relationships between Mtb activity and the 4-anilinoquinoline/quinazoline scaffold that could be used to inform a medicinal chemistry, trajectory for enhanced Mtb activity. The most sensitive structural changes were found to be in the ring appended to the aniline rather than in the quin(az)oline core. This body of work provides a number of exciting starting points for further optimization. However, the failure to achieve complete parasite kill led us to deprioritize the series due to the potential for resistance to develop. The mechanism of anti-Mtb activity of these quin(az)olines has yet to be defined. These compounds were originally prepared as inhibitors of human kinases targeting the ATP-binding site, a rational starting hypothesis for the mechanism of action is that the effects of these compounds are mediated by inhibition of Mtb kinases. However, it is possible that the observed phenotypes may originate from modulation of other, non-kinase ATP-binding proteins in the organism.
Gefitinib, erlotinib, and lapatinib have previously been reported to inhibit the intracellular growth of Mtb. The authors provided multiple lines of evidence that inhibition of the host target epidermal growth factor receptor (EGFR) was responsible for this activity. 15 However our results suggest that there may be further targets involved, with the benzyl substituent presence in the molecule showing a pivotal effect to potency, as is highlighted by the activity of 30 vs 34. The present results may help define a medicinal chemistry trajectory towards antitubercular compounds with targets in both the host and the parasite itself. Such dual acting compounds might offer advantages in efficacy and/or reduction in propensity for resistance. i Pr2NEt (2.5 eq.) were suspended in ethanol (10 mL) and refluxed for 18 h. The crude mixture was purified by flash chromatography using EtOAc:hexane followed by 1-5 % methanol in EtOAc; After solvent removal under reduced pressure, the product was obtained as a free following solid or recrystallized from ethanol/water. 156.6, 150.5, 140.4, 136.9, 129.7, 128.5 (2C, s), 127.9, 127.7 (2C,  s), 127.1, 126.3 (2C, s), 119.4, 114.8 (2C, s), 105.8, 102.0 N-(4-(benzyloxy)phenyl)-6-methoxyquinazolin-4-amine (4) + calcd for C21H17N3O2F: 362.1305 found = 362.1296; LC t R = 4.25 min, >98% Purity. -[(2-fluorophenyl) 4-((4-((4-fluorobenzyl)oxy) 
4-{[4-(benzyloxy)phenyl]amino}quinazolin-6-ol
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